Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Open-Angle Glaucoma
NCT06792422Phase 4Recruiting
- Sponsor
- Rigshospitalet Glostrup
- Start
- Jan 2025
- Primary completion
- Aug 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in open-angle glaucoma (OAG), sponsored by Rigshospitalet Glostrup. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT06792422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792422.